Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF TASLY PHARMACEUTICAL FOR THE SIX MONTHS ENDED 30 JUNE 2025

On 15 August 2025, Tasly Pharmaceutical released its interim report for the six months ended 30 June 2025.

Tasly Pharmaceutical Group Co., Ltd.（天士力醫藥集團股份有限公司）("**Tasly Pharmaceutical**") is a company incorporated in the People's Republic of China. The shares of Tasly Pharmaceutical are listed on the Shanghai Stock Exchange. As of the date of this announcement, Tasly Pharmaceutical is owned as to approximately 28% equity interest by China Resources Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**"), through its non-wholly owned subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd（華潤三九醫藥股份有限公司）, and is accounted for as a subsidiary of the Company.

On 15 August 2025, Tasly Pharmaceutical released its interim report for the six months ended 30 June 2025 (the "**Tasly Pharmaceutical Unaudited Financials**"). Set out below are the key financial information of the Tasly Pharmaceutical Unaudited Financials:

	For the six months ended 30 June		**Increase/decrease**
	2025	**2024**	
	(RMB)	*(RMB)*	*(%)*
	(unaudited)	(unaudited)	
Revenue	**4,288,208,856.32**	4,371,739,444.62	-1.91
Net profit attributable to the shareholders of the listed company	**774,696,532.98**	662,308,440.34	16.97
Net profit attributable to the shareholders of the listed company (after extraordinary gains or losses)	**640,048,464.61**	734,591,718.12	-12.87
Net cash flow from operating activities	**789,592,279.79**	886,713,703.55	-10.95
Basic earnings per share *(RMB/share)*	**0.52**	0.44	18.18
Diluted earnings per share *(RMB/share)*	**0.52**	0.44	18.18
Weighted average return on net asset *(%)*	**6.38**	5.29	increased by 1.09 percentage points

	As of 30 June 2025	**As of 31 December 2024**	**Increase/decrease**
	(RMB)	*(RMB)*	(%)
	(unaudited)	(audited)	
Total assets	**15,448,596,787.75**	14,976,295,362.69	3.15
Net assets attributable to shareholders of the listed company	**12,377,391,593.20**	11,903,329,002.35	3.98

The Tasly Pharmaceutical Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company's auditors, and may require adjustment during the course of auditing. The financial information is limited to Tasly Pharmaceutical only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company and should not rely solely on such information.**

For further details of the Tasly Pharmaceutical Unaudited Financials, please refer to the interim report for the six months ended 30 June 2025 published by Tasly Pharmaceutical on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 15 August 2025

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.